Phase I – Other

1,064 trials 249 recruiting

Filter these 1,064 trials by condition, country, sponsor and more.

Open in Search →

A Phase 1b Study of Imvotamab in Severe Systemic Lupus Erythematosus Ended

2023-506499-29-00 Systemic Lupus Erythematosus 2024-02-28
A trial to determine how nanatinostat is absorbed, modified, and removed from the body and the amount of nanatinostat that becomes available… Ended

2023-508184-74-00 Advanced cancer 2024-02-28
Assessment of narrowing of blood vessels after single application of two clascoterone formulations (cream and solution) onto the skin in com… Ended

2023-507241-28-00 Test of vasocontriction properties for classification o 2024-02-26
Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303) Ended

2022-502940-10-00 Advanced Solid Tumors 2024-02-23
This is a clinical trial (study), to be conducted at multiple clinical sites, of an oral study drug (EP262) that will be investigated in adu… Ended

2023-504800-28-00 Chronic Inducible Urticaria 2024-02-23
A study to Assess the Effect of Fluvoxamine (CYP2C19 Inhibitor), Itraconazole (CYP3A4 Inhibitor) and Paroxetine (CYP2D6 Inhibitor) on the Ph… Ended

2023-508382-33-01 Proteinopathies 2024-02-22
A study to test how a new long-acting insulin works in the body of patients with type 2 diabetes during exercise and prolonged fasting. Ended

2023-505012-38-00 Type 2 diabetes 2024-02-21
A research study to look at how CagriSema influences food intake, appetite and emptying of the stomach in people with excess body weight Ended

2023-504792-24-00 Obesity 2024-02-20
A study to learn how different forms of study medicine tafamidis are taken up into the blood in healthy adults Ended

2023-509241-12-00 aransthyretin amyloid cardiomyopathy 2024-02-15
A SINGLE-CENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF REPEAT DOSES OF ARM210 IN HEAL… Ended

2023-509086-20-00 Cardiac arrhythmias 2024-02-13
A study of how CagriSema works on appetite in people with excess body weight Ended

2023-504782-23-00 Obesity 2024-02-09
MK-7480 Multiple Ascending Dose Study in Healthy Participants Ended

2023-508982-34-00 Non-alcoholic steatohepatitis 2024-02-09
A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis Ended

2023-505127-31-00 Rheumatoid Arthritis 2024-02-08
A trial to learn how baxdrostat affects the heartbeat in healthy participants Ended

2023-506108-23-00 Treatment-resistant hypertension 2024-02-06
Feasibility and tolerability of 28 days intravaginal oxybutynin via the MedRing OAB system Ended

2023-508692-36-00 Overactive bladder 2024-02-06
A Study to Learn If the Study Medicine Called Vepdegestrant Changes How the Body Processes the Other Study Medicine Called Midazolam Ended

2023-508518-40-00 ER+/HER2 positive breast cancer 2024-02-05
Single-dose Study of BMS-986326 at Two Dose Levels in Participants with Atopic Dermatitis Ended

2022-502997-18-00 Atopic Dermatitis 2024-02-02
Randomised, crossover bioavailability clinical trial of oral minoxidil 1 mg, after single and multiple dose administration to healthy volunt… Ended

2023-503796-14-00 Androgenetic alopecia 2024-02-01
Relative Bioavailability and Effect of Food Study With AGMB-129 in Healthy Participants Ended

2023-504460-41-00 Fibrostenotic Crohn’s disease 2024-01-30
A Study to Learn How Different Manufactured Products of the Study Medicine Called Ritlecitinib are Taken up Into the Blood in Healthy Adults… Ended

2023-505603-23-00 ulcerative colitis, Crohn’s Disease, alopecia areata, r 2024-01-29
Effect of cannabidiol on muscle recovery following a single bout of resistance exercise. Ended

2024-513768-24-00 Healthy individuals 2024-01-29
An open-label cocktail drug-drug interaction (DDI) clinical study to assess the effect of multiple oral dosing with leniolisib on the pharma… Ended

2023-507134-25-00 Activated Phosphoinositide 3-Kinase Delta Syndrome 2024-01-29
ADME: A Study to Understand What the Body does to the Study Compound Called PF-07220060 When Taken by Healthy Adults. Ended

2023-507074-40-00 metastatic/advanced breast cancer 2024-01-26
An open-label, single-dose, parallel-group study to evaluate the plasma pharmacokinetics of leniolisib in subjects with impaired hepatic fun… Ended

2023-508519-22-00 Activated Phosphoinositide 3-Kinase Delta Syndrome 2024-01-26